As part of our series of white papers tracking clinical trials activity across the world, GlobalData recently compiled a summary of the clinical trials initiated in Japan. GlobalData captured records of 8,615 clinical trials across all diseases and phases that had a start date between January 01, 2012, and December 31, 2016.
Figure 1: Clinical Trials for the Top Five Indications by Phase in Japan
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The largest number of clinical trials took place in type 2 diabetes, followed by non-small cell lung cancer, breast cancer, gastric cancer, and colorectal cancer. Phase II was the most frequent phase across the major indications, as shown in Figure 1, ranging between 53% and 70% of trials in each indication.
Figure 2: Clinical Trials for the Top Five Indications by Sponsor Type
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataNon-industry sponsors were most common across all major indications, all of which presented with three times as many non-industry sponsors as industry sponsors, with the exception of colorectal cancer, which had five times as many non-industry trials as industry trials (see Figure 2).
